Friday, April 3, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Apr 3, 2026
Chutes & Ladders—Bayer radiology head takes top U.S. pharma spot
background ▾
- •This is a routine personnel announcement roundup with no clinical, regulatory, or material market access implications
BayerEvotecCue BiopharmaCUE-401CUE-501
→ Read original articlePolicy•Fierce Pharma•Apr 2, 2026
Trump slaps 100% duties on imported drugs but leaves plenty of exceptions
background ▾
- •100% tariff on patented drugs/ingredients with 120-180 day implementation timeline, but extensive exemptions significantly narrow actual impact—particularly benefiting large drugmakers already in MFN agreements through January 2029
- •Generics, biosimilars, and orphan drugs are fully exempt, protecting affordable medicines; however, midsize biotech firms reliant on few patented products face material tariff burden without exemption pathways
- •Watch for: midsize biotech response and potential policy adjustments; whether large pharma's prior $100B+ onshoring commitments accelerate; implementation details and trade negotiation outcomes with non-exempted countries
European Union manufacturersJapanese manufacturersKorean manufacturerspatented pharmaceutical productsgeneric drugsbiosimilars
→ Read original articlePolicy•Fierce Pharma•Apr 2, 2026
UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments
background ▾
- •U.K. secures world-first 0% tariffs on pharma exports to U.S., representing a significant trade policy win that addresses a major cost driver for the pharmaceutical sector
- •NHS price increases (25% net price rise via NICE threshold adjustment) and rebate caps through 2028 provide multi-year pricing predictability—critical to reversing the 2024 pharma disinvestment exodus
- •Watch implementation speed and whether the improved investment climate leads to actual reinstatement of paused R&D facilities; early signals from Lilly, GSK, and BMS are positive but described as 'first steps' requiring rapid follow-through
Bristol Myers SquibbAbbVieGSK
→ Read original articlePolicy•Fierce Pharma•Apr 2, 2026
Trump eyes 100% tariff rate for companies that have not struck MFN deals: Bloomberg
background ▾
- •100% tariffs on imported pharmaceuticals will apply only to companies that have not completed MFN pricing deals with the White House, creating stark competitive asymmetry favoring large pharma over mid-sized innovators
- •The Midsized Biotech Alliance argues the policy threatens American biotech innovation by targeting companies with limited product portfolios and insufficient scale to secure MFN exemptions or build U.S. manufacturing capacity
- •Implementation clarity remains uncertain: the interaction between country-specific tariff deals (UK, EU, Switzerland, Japan) and domestic MFN policy, plus reports of possible tiered tariff rates (10-20%) in some cases, require regulatory guidance
AlnylamBioMarinMadrigal
→ Read original articlePolicy•Fierce Pharma•Apr 2, 2026
Poland, Romania must pay Pfizer $2.2B in fight over contested COVID vaccine doses: Belgian court
background ▾
- •Polish and Romanian governments must collectively pay €1.9B to Pfizer for contracted COVID-19 vaccine doses they refused to accept or pay for in 2021–2023.
- •The Brussels court rejected force majeure arguments (Ukraine war, reduced COVID cases) and found no evidence of Pfizer market abuse, establishing that pandemic supply contracts are enforceable despite changed circumstances.
- •Poland is appealing; watch for appellate rulings that could either uphold or overturn this decision and potentially influence other EU member state disputes with vaccine manufacturers.
PfizerBioNTechComirnaty
→ Read original articleMarket Access
Market Access•Fierce Pharma•Apr 2, 2026
Lilly's obesity pill Foundayo gains early blockbuster forecast as analysts float 5M+ prescriptions in 2026
background ▾
- •Foundayo approval and immediate commercial launch via LillyDirect positions Lilly to capture significant share in the rapidly expanding oral obesity market, with consensus forecasts of 5–6M prescriptions and $1.6–2B revenue in 2026.
- •Novo Nordisk's Wegovy pill maintains first-mover advantage with 20,000 prescriptions in two weeks versus Foundayo's nine-month 2026 runway, but Foundayo's no-food-restrictions profile may substantially blunt Wegovy uptake despite the latter's slight price advantage.
- •Watch for: payer coverage decisions and reimbursement rates (expected summer 2025), actual prescription volume in Foundayo's first months, and whether oral GLP-1s expand total obesity treatment demand or primarily shift share between Lilly and Novo.
Eli LillyNovo NordiskFoundayo (orforglipron)Wegovy (semaglutide)Zepbound (tirzepatide)
→ Read original articleMarket Access•Fierce Pharma•Apr 2, 2026
German CDMO Adragos buys French sterile injectables plant from Sanofi
background ▾
- •Adragos acquires a landmark European sterile injectables facility from Sanofi, positioning itself as a top-tier continental CDMO with multi-country manufacturing footprint
- •Sanofi continues divesting manufacturing assets while maintaining long-term supply partnerships, reflecting a shift toward outsourced production models
- •The deal follows Adragos' 2023 acquisition of Sanofi's Japanese facility and a five-year supply agreement, indicating deepening CDMO reliance by major pharma
Adragos PharmaSanofi
→ Read original articleMarket Access•Fierce Biotech•Apr 2, 2026
Premier Radiology acquires teleradiology specialist GLOBIS
background ▾
- •Premier Radiology has completed three acquisitions within 12 months (NationalRad, Metis MD, GLOBIS), signaling aggressive rollup strategy in the fragmented teleradiology market
Premier Radiology ServicesGlobal Imaging Solutions (GLOBIS)
→ Read original articleMarket Access•Fierce Pharma•Apr 2, 2026
BioNTech telegraphs closure of Singapore vaccine facility amid efforts to 'align capacity'
background ▾
- •BioNTech's Singapore facility—originally planned to produce hundreds of millions of mRNA vaccine doses annually—will close by end-February 2027, marking a dramatic retreat from pandemic-era capacity expansion just four years after acquisition
- •The closure reflects a 83% collapse in annual revenues (€17.3B → €2.9B) driven by normalized COVID vaccine demand, mirroring distress across the mRNA vaccine ecosystem (Pfizer, Moderna)
- •Watch for clarity on BioNTech's oncology pipeline execution and leadership transition as co-founders depart to launch a competing mRNA venture; success of late-stage programs will determine viability of the 'immunotherapy powerhouse' repositioning strategy
BioNTechNovartisPfizerComirnaty
→ Read original articleMarket Access•Fierce Pharma•Apr 2, 2026
Rising Stars: The Trade Desk's Elizabeth Keenan finds the rhythm in music and media
background ▾
- •The Trade Desk is actively building and evolving HCP and DTC marketing products with integrations to Crossix and IQVIA for audience targeting and optimization
The Trade DeskBloombergAmnet
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 2, 2026
Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials, validating biotech’s waning interest
background ▾
- •Batoclimab failed to meet primary efficacy endpoint in both phase 3 TED trials despite acceptable safety profile, ending commercial viability of the first-generation FcRn inhibitor despite prior phase 3 success in myasthenia gravis.
- •Post-hoc analysis showed greater proptosis improvements during high-dose versus low-dose periods, suggesting deeper IgG suppression may be necessary but insufficient to overcome the failed primary endpoint.
- •Immunovant is refocusing development resources on IMVT-1402, a second-generation FcRn inhibitor with phase 2b data in Graves' disease expected in 2026, as the broader FcRn class faces repeated setbacks in TED indication.
ImmunovantRoivantHanAllbatoclimabIMVT-1402Vyvgart
→ Read original articleClinical Trials•Fierce Pharma•Apr 2, 2026
Another AstraZeneca Emerald glimmers as Imfinzi, Imjudo delay liver cancer progression
background ▾
- •Emerald-3 hit primary PFS endpoint with the four-drug combination (Imfinzi/Imjudo/TACE/Lenvima), but OS immaturity leaves regulatory path uncertain—similar to Emerald-1, which still awaits final OS data two years post-readout
- •Merck's 2024 failure to achieve OS improvement with Keytruda-Lenvima-TACE despite PFS benefit signals that PFS wins alone are insufficient in locoregional HCC, setting a high bar for AZ's approval prospects
- •A secondary two-drug arm (Imfinzi/Imjudo/TACE without Lenvima) showed 'strong trends' in PFS and OS but was not formally tested; watch for formal analysis and regulatory feedback as AZ discusses strategy with authorities
AstraZenecaMerck & Co.EisaiImfinziImjudoLenvima
→ Read original articleClinical Trials•Fierce Biotech•Apr 2, 2026
Alto halts work on PDE4 inhibitor after phase 2 schizophrenia failure
background ▾
- •ALTO-101 failed its primary efficacy endpoint in phase 2 schizophrenia trial, prompting immediate program halt and redirection of resources to ALTO-207
- •Post-hoc analyses showed 'nominally significant' effects in a pre-specified cognitively impaired subgroup and directional EEG improvements, suggesting the trial design may have been underpowered or the patient population poorly selected
- •Monitor Alto's ALTO-207 phase 2b initiation in treatment-resistant depression and ALTO-300 in major depressive disorder, as investor focus has shifted away from the failed cognitive impairment indication
Alto NeurosciencesAmgenALTO-101ALTO-207ALTO-203
→ Read original articleClinical Trials•Fierce Biotech•Apr 2, 2026
Epia Neuro launches with BCI device to help stroke patients rework brain signals
background ▾
- •Epia Neuro's minimally invasive, implantable BCI with integrated AI and grip-assist prosthetics enters development phase targeting stroke recovery—a large unmet need—with first-in-human studies planned for late 2026.
- •The BCI landscape is rapidly consolidating with multiple competitors (Neuracle, Neuralink, Epia) advancing toward or achieving human trials, signaling investor confidence but also increased competition for regulatory approval and clinical adoption.
- •Watch for: late-2026 first-in-human data from Lenox Hill; regulatory pathway clarity (FDA likely IND/IDE pathway); clinical efficacy benchmarks vs. Neuralink and Neuracle; and longer-term timeline to commercial viability (likely 2028+).
Epia NeuroNeuracle TechnologyNeuralink
→ Read original articleClinical Trials•Fierce Biotech•Apr 2, 2026
‘Portfolio assessment’ prompts Ferring to terminate 2 fertility trials
background ▾
- •Ferring terminated two fertility trials with 416 patients enrolled as part of portfolio optimization, not due to safety signals, indicating strategic deprioritization of exploratory reproductive medicine programs
- •The decision follows a pattern of contraction in Ferring's reproductive medicine pipeline, including cancellation of the male infertility study (Adam) in 2024 and commercial slowdown of Rebyota, suggesting tighter R&D resource allocation post-reorganization
- •Monitor whether FE999302 is completely abandoned or shelved, and track Ferring's remaining observational Rekovelle study in Asia and any future reproductive medicine investments despite record 2.5B euro revenues
Ferring PharmaceuticalsFE999302RekovelleMenopur
→ Read original article